Barinthus Biotherapeutics
BRNS
BRNS was delisted on the 8th of September, 2026.
15 hedge funds and large institutions have $7.84M invested in Barinthus Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 14 → 15 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.23% less ownership
Funds ownership: 22.76% → 22.53% (-0.23%)
1% less capital invested
Capital invested by funds: $7.89M → $7.84M (-$46.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$69.5K |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$16.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$9.66K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$7.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$657 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$82.1K |
| 2 |
GS
GTS Securities
Miami,
Florida
|
-$41.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$27.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$6.62K |
BRNS Hedge Fund Activity: Q2 2026 in Review
15 of the 8,326 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q2 2026, worth a combined $7.84M — down 0.58% from $7.89M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BRNS positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $69.5K. The largest seller was Renaissance Technologies, cutting an estimated $82.1K.
- 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q2 2026, up from 14 in Q1 2026.
- Funds reported $7.84M of Barinthus Biotherapeutics stock for Q2 2026, down 0.58% quarter-over-quarter.
- 3 funds opened new Barinthus Biotherapeutics positions in Q2 2026 and 2 closed out, a net change of +1 holder.
- The largest Barinthus Biotherapeutics buyer in Q2 2026 was Morgan Stanley, an estimated $69.5K added.
- The largest Barinthus Biotherapeutics seller in Q2 2026 was Renaissance Technologies, an estimated $82.1K sold.
Based on aggregated 13F filings for Q2 2026.